Drug intelligence / Profile preview

AP39

Development stage: Preclinical
Lead developer: MitoRx
Modality: Small Molecules

Overview

AP39 is a mitochondria-targeting hydrogen sulfide (H2S) donor. It consists of a triphenylphosphonium motif linked to an H2S-donating moiety (dithiolethione). AP39 increases intracellular H2S levels, which can protect against ischemia/reperfusion injury and has been shown to induce weight loss by reducing fatty liver and obesity in mice fed a high-fat diet. It also acts as a photosensitizer and thioredoxin inhibitor.

Targets

ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on AP39.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP39.

Explore the full profile